Antibody-Drug Conjugates (ADCs) are a fundamental technology in modern tumor-targeted therapy with their ‘tripartite integrated design’ of ‘precision carrier - stable linker - potent payload’: The ...

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the development ...

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Revvity has launched pHSense™ reagents, a plate-based technology designed to monitor receptor and antibody-drug conjugate (ADC) internalization in high-throughput workflows. The reagents use a ...

SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

In this interview, Grace Liu from Sino Biological shares her expertise on Antibody-Drug Conjugates (ADCs), a revolutionary cancer therapy combining precision targeting with potent cytotoxic drugs.